162 related articles for article (PubMed ID: 38617018)
1. Long-Term SGRQ Stability in a Cohort of Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease.
Choate R; Holm KE; Sandhaus RA; Mannino DM; Strange C
Int J Chron Obstruct Pulmon Dis; 2024; 19():889-900. PubMed ID: 38617018
[TBL] [Abstract][Full Text] [Related]
2. Characteristics associated with SF-36 in alpha-1 antitrypsin deficiency-associated COPD: a cross-sectional analysis.
Choate R; Holm KE; Sandhaus RA; Mannino DM; Strange C
BMC Pulm Med; 2024 Mar; 24(1):138. PubMed ID: 38500152
[TBL] [Abstract][Full Text] [Related]
3. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
4. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
5. The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease.
Lin YX; Xu WN; Liang LR; Pang BS; Nie XH; Zhang J; Wang H; Liu YX; Wang DQ; Xu ZY; Wang HW; Zhang HS; He ZY; Yang T; Wang C
Chin Med J (Engl); 2009 Dec; 122(24):2939-44. PubMed ID: 20137478
[TBL] [Abstract][Full Text] [Related]
6. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency.
Campos MA; Alazemi S; Zhang G; Wanner A; Sandhaus RA
COPD; 2009 Feb; 6(1):31-40. PubMed ID: 19229706
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
[TBL] [Abstract][Full Text] [Related]
8. Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?
Stockley RA; Edgar RG; Starkey S; Turner AM
Respir Res; 2018 Jul; 19(1):137. PubMed ID: 30029692
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
Stoller JK; Aboussouan LS; Kanner RE; Wilson LA; Diaz P; Wise R;
Ann Am Thorac Soc; 2015 Dec; 12(12):1796-804. PubMed ID: 26653189
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with Alpha-1 antitrypsin deficiency (EMPROVE).
Hogarth DK; Delage A; Zgoda MA; Nsiah-Dosu S; Himes D; Reed MF
Respir Med; 2024 Apr; 224():107565. PubMed ID: 38364975
[TBL] [Abstract][Full Text] [Related]
11. The modified Medical Research Council dyspnoea scale is a good indicator of health-related quality of life in patients with chronic obstructive pulmonary disease.
Hsu KY; Lin JR; Lin MS; Chen W; Chen YJ; Yan YH
Singapore Med J; 2013 Jun; 54(6):321-7. PubMed ID: 23820542
[TBL] [Abstract][Full Text] [Related]
12. Impact of comorbidities on COPD-specific health-related quality of life.
Burgel PR; Escamilla R; Perez T; Carré P; Caillaud D; Chanez P; Pinet C; Jebrak G; Brinchault G; Court-Fortune I; Paillasseur JL; Roche N;
Respir Med; 2013 Feb; 107(2):233-41. PubMed ID: 23098687
[TBL] [Abstract][Full Text] [Related]
13. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
[TBL] [Abstract][Full Text] [Related]
14. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
15. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity.
Lee H; Jhun BW; Cho J; Yoo KH; Lee JH; Kim DK; Lee JD; Jung KS; Lee JY; Park HY
Int J Chron Obstruct Pulmon Dis; 2017; 12():3301-3310. PubMed ID: 29180860
[TBL] [Abstract][Full Text] [Related]
16. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
[TBL] [Abstract][Full Text] [Related]
17. Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease.
Ferrari R; Tanni SE; Caram LM; Naves CR; Godoy I
Health Qual Life Outcomes; 2011 Dec; 9():112. PubMed ID: 22152155
[TBL] [Abstract][Full Text] [Related]
18. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
19. Impact of the COVID-19 pandemic on well-being and quality of life of patients with alpha-1-antitrypsin deficiency.
Werdecker C; Bals R
Respir Res; 2023 Oct; 24(1):258. PubMed ID: 37880685
[TBL] [Abstract][Full Text] [Related]
20. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.
Lenferink A; Brusse-Keizer M; van der Valk PD; Frith PA; Zwerink M; Monninkhof EM; van der Palen J; Effing TW
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011682. PubMed ID: 28777450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
